scholarly journals Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4α gene

Hepatology ◽  
2008 ◽  
Vol 48 (5) ◽  
pp. 1528-1539 ◽  
Author(s):  
Chuan Yin ◽  
Yong Lin ◽  
Xin Zhang ◽  
Yue-Xiang Chen ◽  
Xin Zeng ◽  
...  
Hepatology ◽  
2011 ◽  
Vol 54 (6) ◽  
pp. 2036-2047 ◽  
Author(s):  
Xin Zeng ◽  
Yong Lin ◽  
Chuan Yin ◽  
Xin Zhang ◽  
Bei-Fang Ning ◽  
...  

2010 ◽  
Vol 70 (19) ◽  
pp. 7640-7651 ◽  
Author(s):  
Bei-Fang Ning ◽  
Jin Ding ◽  
Chuan Yin ◽  
Wei Zhong ◽  
Kun Wu ◽  
...  

Oncotarget ◽  
2016 ◽  
Vol 7 (19) ◽  
pp. 27408-27421 ◽  
Author(s):  
Cai-Feng Jiang ◽  
Liang-Zhi Wen ◽  
Chuan Yin ◽  
Wen-Ping Xu ◽  
Bin Shi ◽  
...  

2015 ◽  
Vol 37 (6) ◽  
pp. 2257-2264
Author(s):  
Wenwen Sun ◽  
Friederike Katharina Kosyna ◽  
Wolfgang Jelkmann ◽  
Reinhard Depping

Background: Increased red blood cell count (Erythrocytosis) is an important paraneoplastic syndrome of hepatocellular carcinoma (HCC) and is a significant risk factor for lethal lung artery thromboembolism. HCC-associated erythrocytosis is partially caused by the ability of several HCC cells to produce erythropoietin (EPO). Prolyl-4-hydroxylase 2 (PHD2) is an enzyme encoded by the gene EGLN1. The best-known function of PHD2 is to mediate the oxygen-dependent degradation of the labile α-subunit of hypoxia-inducible factor (HIF). However, there is increasing evidence that PHD2 also regulates HIF-independent pathways by interacting with other substrates. Methods: In the EPO-producing human HCC cell line HepG2, the expression of PHD2 gene was silenced with siRNA. EPO production was estimated using quantitative PCR and ELISA. Results: In HepG2 cells, PHD2 suppresses the activity of TGF-β1 pathway and consequently maintains the expression of hepatocyte nuclear factor-4α (HNF-4α), an important transcription factor promoting the EPO expression in hepatocytes. PHD2 knockdown caused a marked reduction of EPO production. HIF seemed not to be involved in this biology. Conclusion: Our findings show that PHD2 represents a potential contributing factor for HCC-associated erythrocytosis. Selective inhibition of PHD2 in HCC cells might be considered as a new way to manage erythrocytosis in HCC patients.


Hepatology ◽  
2013 ◽  
Vol 58 (6) ◽  
pp. 1964-1976 ◽  
Author(s):  
Chuan Yin ◽  
Pei-Qin Wang ◽  
Wen-Ping Xu ◽  
Yuan Yang ◽  
Qing Zhang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document